Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Franssen

Showing results (321-330 of 344) with videos related to

Pageof 35
Sort By:
Health and Quality of Life Outcomes|February 4, 2021
Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19Felipe V C Machado, Roy Meys, Jeannet M Delbressine, et al.
Therapeutic Advances in Respiratory Disease|September 28, 2019
Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitationYvonne M J Goërtz, Martijn A Spruit, Alex J Van 't Hul, et al.
BMJ (Clinical Research Ed.)|March 5, 2026
Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS))Rachel E Jordan, Spencer J Keene, Frits M E Franssen, et al.
ERJ Open Research|December 10, 2025
Quality of life associated with chronic cough in the multinational Burden of Obstructive Lung Disease study: a cross-sectional studyHazim Abozid, Emiel F M Wouters, Hamid Hacene Cherkaski, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
The Lancet. Respiratory Medicine|November 28, 2025
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) modelHnin W W Aung, Kristina Vermeersch, Hamish J C McAuley, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 20, 2019
ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseasesThomas Radtke, Sarah Crook, Georgios Kaltsakas, et al.
Annals of the American Thoracic Society|June 1, 2023
Rehabilitation for People with Respiratory Disease and Frailty: An Official American Thoracic Society Workshop ReportMatthew Maddocks, Lisa J Brighton, Jennifer A Alison, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Pageof 35

Showing results (321-330 of 344) with videos related to

Sort By:
Pageof 35
Health and Quality of Life Outcomes|February 4, 2021
Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19Felipe V C Machado, Roy Meys, Jeannet M Delbressine, et al.
Therapeutic Advances in Respiratory Disease|September 28, 2019
Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitationYvonne M J Goërtz, Martijn A Spruit, Alex J Van 't Hul, et al.
BMJ (Clinical Research Ed.)|March 5, 2026
Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS))Rachel E Jordan, Spencer J Keene, Frits M E Franssen, et al.
ERJ Open Research|December 10, 2025
Quality of life associated with chronic cough in the multinational Burden of Obstructive Lung Disease study: a cross-sectional studyHazim Abozid, Emiel F M Wouters, Hamid Hacene Cherkaski, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
The Lancet. Respiratory Medicine|November 28, 2025
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) modelHnin W W Aung, Kristina Vermeersch, Hamish J C McAuley, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 20, 2019
ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseasesThomas Radtke, Sarah Crook, Georgios Kaltsakas, et al.
Annals of the American Thoracic Society|June 1, 2023
Rehabilitation for People with Respiratory Disease and Frailty: An Official American Thoracic Society Workshop ReportMatthew Maddocks, Lisa J Brighton, Jennifer A Alison, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Pageof 35